Eikon Therapeutics (EIKN) is trading up at $7.55 (+3.00%), as of the latest quote. It is a Russell 2000 constituent in the Health Care sector.
| Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|
| Income statement | ||||
| Operating income | −$71.4M | −$109.6M | −$87.3M | −$93.4M |
| Net income | −$68.2M | −$105.2M | −$83.0M | −$88.4M |
| EPS (diluted) | −$26.91 | −$36.94 | −$2.46 | −$1.63 |
| Balance sheet | ||||
| Cash and equivalents | $204.6M | $136.6M | $161.2M | $142.6M |
| Total assets | — | — | $850.8M | $779.6M |
| Total liabilities | — | — | $300.2M | $313.1M |
| Shareholders' equity | −$640.1M | −$737.5M | $550.7M | $466.5M |
| Cash flow | ||||
| Operating cash flow | −$54.5M | −$32.7M | −$89.8M | −$65.0M |
| Capital expenditure | $22.4M | $21.7M | $262.0K | $251.0K |
| Free cash flow | −$76.9M | −$54.5M | −$90.1M | −$65.2M |
From Eikon Therapeutics's 10-Q filings with the SEC. Each period shows the latest figure the company has reported for it, including restatements. Filings on SEC EDGAR →
No recent news mentioning Eikon Therapeutics in our feed yet.